Psychiatry

Leslie Citrome, MD, on new NEI Spring Congress data on adjunctive lumateperone for major depressive disorder and how clinicians can weigh efficacy, tolerability, and next-step treatment decisions.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Network meta-analysis suggests lumateperone add-on therapy improves MDD symptoms most, with minimal weight gain and placebo-like akathisia risk.

Real-world data show zuranolone improved postpartum depression symptoms by Day 15 with sustained benefit through Day 45.

Centanafadine's FDA priority review signals potential innovation in ADHD treatment, offering a new nonstimulant option for diverse patient needs.

This episode reviews intranasal epinephrine use, pediatric atopic dermatitis data, dementia screening tools, adolescent TMS, and oral PCSK9 therapy.

New phase 3 data reveals lumateperone significantly boosts remission rates in adults with major depressive disorder, offering hope for lasting relief.

Gus Alva, MD, previews 2026 research directions and explains why sleep assessment and sleep disorders may become a bigger focus in routine care.

Gus Alva, MD, reviews the current clinical research landscape for psychedelics and discusses how PCPs can effectively counsel patients on safety and expectations.

Psychiatrist Gus Alva, MD, discusses newer, faster depression screening approaches that primary care clinicians can implement.

Your daily dose of the clinical news you may have missed.

Gus Alva, MD, reviews key 2025 psychiatry advances, including non-monoaminergic approaches to MDD and newer targets in schizophrenia care.

The mobile-based program targets cognitive processes underlying attention and is intended for use alongside medication, therapy, or education.

A population-based study finds stimulant prescribing accelerated after 2020, with the largest increases among adults and women.

Flow Therapeutics announced approval of its Flow-100 tDCS therapy for depression, which could expand access to non-pharmacologic care and will be available in the US in H2 2026.

Adolescents acquiring smartphones at 12 showed increased risk for depression, obesity and sleep disturbances, according to a study of more than 10,000 youths.

Psychiatric comorbidities affect 25% of AD patients. Here, a check list on when to screen, when to refer, and how to prevent accumulated psychological burden in primary care.

A regular focus on mental heatlh during follow-ups with patients who have atopic dermatitis can be integrated simply with a few thoughtful questions.

Mental health apps show high initial uptake but moderate adherence, revealing key factors for improving user retention in clinical trials.

Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.

Controlling atopic dermatitis signs and symptoms early can alter social, emotional, and functional outcomes, sometimes dramatically.

Emotional red flags in AD, eg, sleep loss, isolation, hopelessness, often go unseen. Quick screening questions can surface the real burden individuals carry.

Growing up with AD carries lifelong emotional consequences. Clinicians who recognize these developmental risks can better support patients at every stage.

Up to 1 in 4 patients with atopic dermatitis face anxiety or depression. Primary care clinicians are key to identifying risk and supporting mental well-being.

UK neurodivergent adults report strong views on neurodiversity terminology, emphasizing correct usage and its role in stigma, identity, and communication.